Cite
HARVARD Citation
van den Bent, M. et al. (2021). Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro-oncology. 23 (8), p. 1415. [Online].